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Abstract
Heart failure with a preserved ejection fraction (HFpEF) is associated with multiple
comorbidities, such as old age, hypertension, type 2 diabetes and obesity and is more
prevalent in females. Although the male obese ZSF1 rat has been proposed as a suit-
able model to study the development of diastolic dysfunction and early HFpEF, studies
in female animals have not been performed yet. Therefore, we aimed to characterize
the cardiac phenotype in female obese ZSF1 rats and their lean counterparts. Addition-
ally, we aimed to investigate whether differences exist in disease progression in obese
male and female ZSF1 rats. Therefore, male and female ZSF1 rats, lean as well as
obese (N = 6-9/subgroup), were used. Every two weeks, from 12 to 26 weeks of age,
systolic blood pressure and echocardiographic measurements were performed, and
venous blood was sampled. Female obese ZSF1 rats, as compared to female lean
ZSF1 rats, developed diastolic dysfunction with cardiac hypertrophy and fibrosis in the
presence of severe dyslipidemia, increased plasma growth differentiation factor 15 and
mild hypertension, and preservation of systolic function. Although obese female ZSF1
rats did not develop hyperglycemia, their diastolic dysfunction was as severe as in the
obese males. Taken together, the results from the present study suggest that the female
obese ZSF1 rat is a relevant animal model for HFpEF with multiple comorbidities, suit-
able for investigating novel therapeutic interventions.
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Introduction
Heart failure (HF) is a growing global health problem, with high morbidity and mortality, and
the leading cause for hospitalizations in patients above 65 years of age [1]. HF can be divided
into three types: HF with a preserved ejection fraction (HFpEF), HF with mid-range ejection
fraction (HFmrEF) and HF with reduced ejection fraction (HFrEF). HFpEF is characterized
by an increase in left ventricular (LV) wall thickness and/or left atrial size as indication of
increased LV filling pressures. Additionally, impaired LV filling, also referred to as diastolic
dysfunction, is observed in these patients [2]. Although diastolic dysfunction is highly preva-
lent in HFpEF, the disease is viewed as a complex syndrome in which cardiac and non-cardiac
determinants contribute to the impairment of the cardiovascular reserve [3, 4]. Conversely,
HFrEF is defined by a lack of contractility with ejection fraction (EF) <40%, caused by an
insult that leads to myocyte loss and functional impairment [5]. HFmrEF is the subgroup of
patients with symptoms of HF and an EF ranging from 40 to 49%. Although effective treat-
ment options exist for HFrEF and HFmrEF, this is not true for HFpEF [6]. Its underlying
mechanisms are poorly understood and are further complicated by the presence of multiple
interrelated comorbidities such as obesity, diabetes mellitus type 2 and hypertension [7, 8].
HFpEF is more predominant in elderly post-menopausal women and is closely associated with
the presence of hypertension as well as excess weight or obesity [9, 10]. To better understand
the underlying mechanisms and the effects of new therapies, animal models of early HFpEF
are required. As it is not possible to mimic every detail of the disease in an animal model, the
focus should be on specific pathophysiological aspects of early HFpEF in patients [11, 12].
In this regard, the male obese Zucker diabetic fatty/Spontaneously hypertensive heart fail-
ure F1 hybrid (ZSF1) rats have been proposed as an animal model for HFpEF [13, 14]. This
model develops by crossing two rat strains with two different leptin mutations (fa and facp):
the lean female Zucker diabetic fatty rat (ZDF; +/fa) and the lean male spontaneously hyper-
tensive heart failure rat (SHHF; +/facp) [15]. Previous studies have shown that male obese
ZSF1 rats develop diastolic dysfunction between 10 and 20 weeks of natural aging with con-
centric LV remodeling and hypertrophy [16].
To date, all studies using this model to mimic human HFpEF disease have been performed
in male animals, while clinical prevalence of HFpEF is higher in women. In non-obese rat
strains, male rats are more prone to develop HF compared to females and often the phenotype
in females is milder compared to their male counterparts [17, 18]. As a result, female animals
are often not included in experimental studies. Consequently, we aimed to characterize the
cardiac phenotype in female obese ZSF1 rats and their lean counterparts in the current study.
Additionally, it is not clear whether the disease progression is more severe in women com-
pared to men. Therefore, we also aimed to investigate whether differences exist in disease pro-
gression in obese male and female ZSF1 rats. Our findings demonstrate that female obese
ZSF1 rats develop diastolic dysfunction compared to lean female ZSF1 rats and that severity
and progression of the disease within the timeframe of the study were similar between male
and female obese ZSF1 rats. This indicates that female obese ZSF1 rats could be considered a
representative model for interventional studies on diastolic dysfunction.
Materials and methods
Animals
All procedures were approved by the Animal Ethics Committee of the University of Utrecht
(CCD: AVD115002016462) and were in accordance with the Dutch Codes of Practice for the
Care and Use of Animals for Scientific Purposes. Experiments were conducted in nine-week
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old male lean (N = 8), male obese (N = 9), female lean (N = 6) and female obese (N = 8) ZSF
rats obtained from Charles River (Kingston, MA, USA) that were co-housed in a climate-con-
trolled facility with a 12-hour light/dark cycle. As the obese rats contain two different leptin
mutations (fa and facp), they become hyperphagic and develop obesity naturally. Rats had
access to water and standard rat chow (CRM-E; Special Diet Services, Witham, Essex, UK) ad
libitum. From 12 weeks to 26 weeks of age, as described previously [19], systolic blood pressure
was measured every two weeks via tail-cuff plethysmography in awake rats. At 12 weeks and
every two weeks from 18 to 26 weeks of age echocardiography was performed and blood sam-
pled from the tail vein in anesthetized rats. Body weight was monitored every week. After the
last measurements, rats were administered buprenorphine (0.015 mg/kg) and were anaesthe-
tized with isoflurane (4% for induction, 2.5% for maintenance) for terminal measurements. At
the end, rats were euthanized by exsanguination via the femoral artery and organs were har-
vested and weighed.
Echocardiographic evaluation
Transthoracic echocardiography was performed with a digital ultrasound machine (Sonos
5500, Philips Research, Eindhoven, the Netherlands) and a 15 MHz linear array transducer
(Hewlett Packard, Palo Alto, CA). Animals were anesthetized with isoflurane (3.5–4% for
induction and 2.5% for maintenance) and placed in supine position on a heating pad. Two-
dimensional B-mode cine loops were recorded in the parasternal long-axis and the midpapil-
lary short-axis views. LV volume was calculated with the area-length method at end-diastole
and end-systole in the parasternal long-axis view [20]. Cardiac output and ejection fraction
were then calculated from these LV volumes. Systolic and diastolic wall thickness and cavity
dimensions were recorded in M-mode in the short-axis view. Images from apical 4-chamber
view were acquired to evaluate LV filling and diastolic function. Mitral flow velocity tracings
were obtained with pulsed-wave Doppler. Peak early E (E wave) filling velocities were mea-
sured. Tissue Doppler Imaging was used to obtain early (e’) diastolic velocity at the medial
mitral annulus. For evaluation of diastolic dysfunction, the ratio of E over e’ was calculated.
Volumes and dimensions were normalized for body surface area [21]. Typical study duration
was 15 min. The acquisitions were coded for blinded analysis. The recordings were analyzed
offline using the software present on the system and the variables were measured in at least
three heart beats at end-diastole and end-systole.
Plasma measurements
Immediately after each echocardiography session, a blood sample of 0.5 ml was drawn from
the tail vein into EDTA anticoagulant-coated tubes, while the rats were still under anesthesia.
Plasma was extracted by centrifugation at 3500 x g for 15 minutes at 4˚C and used for determi-
nation of plasma glucose, cholesterol and triglycerides (DiaSys Diagnostic Systems GmbH,
Cholesterol FS, Triglycerides FS, Glucose GOD FS, Waterbury, CT, USA). Circulating GDF15
levels were measured with a rGDF15 ELISA (MGD150, Quantikine ELISA, R&D systems Inc.,
Minneapolis, MN). Before use, plasma samples were prediluted 1:50 with dilution buffer
according to the manufacturers protocol.
Histological analysis
Deparaffinized cardiac sections were stained with Picro Sirius Red (Sigma-Aldrich, Zwijn-
drecht, the Netherlands) for 25 min, differentiated in 0.2 HCl and rinsed with aquadest, fol-
lowed by dehydration. Of each section, 20 non-overlapping fields were imaged with a
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fluorescence microscope with a polarizing filter (Olympus BX51, magnification 100x). Analy-
sis was performed in a blinded fashion using Adobe Photoshop and ImageJ Software.
To distinguish between collagen type I and III fibers, eight fields were examined in the mid-
myocardial layer of each slide and analyzed using a polarization filter (magnification 20x).
Blood vessels, including perivascular collagen, tissue ruptures and folds were excluded. The
birefringence capacity of the collagen fibers is used to differentiate between the thick collagen
fibers (red-yellow, Type I) and the thin fibers, with a lower birefringence, (green, Type III).
The area occupied by collagen type I and type III fibers was measured and expressed as per-
centage of the myocardial area. All measurements were performed using a microscopy image
analysis system (Impak C, Clemex Vision Image analysis system, Clemex Technologies, Que-
bec, Canada).
Deparaffinized cardiac sections for lectin staining were subjected to 3% hydrogen peroxide
in PBS for 30 min, followed by heat-induced antigen retrieval in citrate/HCl buffer (pH 6.0)
for 15 min. To visualize capillaries, sections were first blocked in avidin and biotin blocking
solution (Abcam). Sections were then incubated overnight at 4˚C with biotin labelled anti-Lec-
tin (1:200, Sigma-Aldrich), after which HRP-bound streptavidin (1:500, Bio-Rad Laboratories)
was added to the samples for 60 min. Finally, 3,30-diaminobenzidine solution was applied to
the sections twice, 6 min each. Four non-overlapping fields in the sub-endocardium were
imaged and analyzed in a blinded fashion.
Gomori staining was performed using the Reticulum Stain Kit (Diagnostic Biosystems)
according to manufacturer’s instructions. Slides were counterstained for 3 min using Nuclear
Fast Red and imaged. Cross-sectional areas of cardiomyocytes with clearly visible nuclei, and
height to width ratios not exceeding 1:2, were measured in 4 non-overlapping fields in a
blinded fashion using Clemex software.
Statistics
Data are presented as mean ± SEM. Groups were compared by 2-way ANOVA for repeated
measurements followed by Bonferroni post hoc test using GraphPad Prism 7.0 software
(GraphPad, San Diego, CA). Pre-terminal and terminal variables at 26 weeks of age were com-
pared by 2-way ANOVA followed by Tukey multiple comparison test. P<0.05 was considered
significant.
Results
Metabolic profile
Obese ZSF1 rats showed a rapid weight gain on a regular chow diet. Body weight was signifi-
cantly higher in both male and female obese ZSF1 rats compared to their lean counterparts
(Fig 1A). Male animals were in general heavier compared to female animals. Systolic blood
pressure was similar in both obese and lean ZSF1 rats, and no sex differences were observed
(Fig 1B). Dyslipidemia was present in both male and female obese ZSF1 rats compared to lean
ZSF1 rats (Fig 1C and 1D) and was more pronounced in female obese than in male obese rats.
Surprisingly, only the obese male ZSF1 rats became hyperglycemic, with the female obese rats
showing similar glucose levels as their lean littermates (Fig 1E).
Cardiac structure and function
Analysis of the left ventricle in the parasternal long-axis view showed an increased end-dia-
stolic volume (EDV) in female obese ZSF1 rats as compared to lean female ZSF1 rats, while no
differences were observed between male obese ZSF1 rats and their lean counterparts (Table 1).
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Fig 1. Both male and female obese ZSF1 rats exhibit obesity, dyslipidemia and mild hypertension. A) Body weight was
markedly higher in the obese ZSF1 rats compared to their lean counterparts. B) Systolic blood pressure was similar in all the
groups, with a range of 140–150 mmHg over time. C) Triglycerides and D) cholesterol levels were markedly elevated in both
male and female obese ZSF1 rats. E) Plasma glucose levels were only elevated in male obese rats compared to their lean
counterparts. Means ± SEM. Male obese N = 9; female obese N = 8; male lean N = 8 and female lean N = 6; � male obese vs. male
lean; † male obese vs. female obese; ‡ female obese vs. female lean; § male lean vs. female lean. One symbol P<0.05, two symbols
P<0.01, three symbols P<0.001.
https://doi.org/10.1371/journal.pone.0232399.g001
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This increased EDV in female obese ZSF1 rats is likely due to their much larger body weight,
as EDV normalized for body surface area (BSA) was similar between obese and lean females
(Fig 2A). Similar patterns were found in end-systolic volume (ESV) and stroke (SV) volume,
with no significant differences between obese and lean rats after normalizing for BSA.
Together with the lower heart rate observed in the obese rats, cardiac index was lower in obese
males compared to their lean counterparts (Fig 2B).
However, ejection fraction was not different between obese and lean animals during the
whole experimental period (Fig 2C).
Tissue Doppler Imaging analysis showed that the E/e’ ratio was significantly increased in
obese ZSF1 compared to lean ZSF1 rats throughout the study: from 12 to 26 weeks of age (Fig
3A). No significant differences were observed in the severity of diastolic dysfunction between
obese male and female animals. When compared to their lean counterparts, both male and
female obese ZSF1 rats showed higher LV mass, as calculated with echocardiography. No dif-
ferences were observed between obese males and females. These echocardiography measure-
ments of LV mass were confirmed at autopsy, with obese animals showing a higher heart
Table 1. Terminal data at 26 weeks of age, expressed as absolute values and per body surface area.
Female lean (n = 6) Female obese (n = 8) Male Lean (n = 8) Male obese (n = 9) p-values
Obesity Sex Interaction
Body weight, g 258 ± 2 519 ± 9‡‡‡ 445 ± 7§§§ 604 ± 15���††† <0.001 <0.001 <0.001
BSA, cm2 49 ± 0.4 77.5 ± 1‡‡‡ 71.3 ± 0.8§§§ 88.1 ± 1.5���††† <0.001 <0.001 <0.001
Heart rate, bpm 397 ± 10.6 336 ± 9.9‡‡‡ 384 ± 6.7 308 ± 6.5��� <0.001 0.02 0.39
EDV, μl 170 ± 16 314 ± 33‡‡ 280 ± 22§ 273 ± 21 0.011 0.17 0.006
EDV, μl/cm2 0.42 ± 0.04 0.51 ± 0.05 0.49 ± 0.04 0.39 ± 0.03 0.83 0.55 0.03
ESV, μl 38 ± 3 95 ± 12‡‡‡ 85 ± 8§§ 96 ± 4 <0.001 0.007 0.008
ESV, μl/cm2 0.10 ± 0.001 0.15 ± 0.02 0.14 ± 0.02 0.14 ± 0.001 0.11 0.35 0.04
SV, μl 130 ± 13 218 ± 23‡ 199 ± 17 176 ± 17 0.095 0.48 0.006
SV, μl/cm2 0.32 ± 0.03 0.35 ± 0.04 0.35 ± 0.03 0.25 ± 0.03 0.35 0.24 0.06
CO, ml/min 51.9 ± 6.5 75.0 ± 9.2 76.0 ± 6.2 54.6 ± 5.5 0.91 0.80 0.004
CO, ml/min/cm2 0.13 ± 0.02 0.12 ± 0.02 0.13 ± 0.01 0.08 ± 0.01� 0.02 0.15 0.10
LVIDd, mm 7.0 ± 0.4 8.4 ± 0.4‡ 8.2 ± 0.2 8.4 ± 0.3 0.019 0.10 0.077
LVIDd, μm/cm2 17.4 ± 1.1 13.6 ± 0.6‡‡ 14.3 ± 0.4§ 12.0 ± 0.5� <0.001 0.001 0.26
LVPWd, mm 1.7 ± 0.07 1.9 ± 0.1 1.5 ± 0.1 2.1 ± 0.07�� <0.001 0.84 0.09
LVPWd, μm/cm2 4.2 ± 0.2 3.1 ± 0.2‡‡‡ 2.7 ± 0.2§§§ 3.0 ± 0.1 0.03 <0.001 <0.001
IVSd, mm 1.5 ± 0.08 1.7 ± 0.09 1.6 ± 0.1 1.8 ± 0.06 0.024 0.19 0.59
IVSd, μm/cm2 3.8 ± 0.2 2.7 ± 0.2‡‡‡ 2.8 ± 0.2§§ 2.7 ± 0.1 <0.001 0.003 0.006
HW (LV+RV), mg 876 ± 27.4 1481 ± 52.2‡‡‡ 1357 ± 28.8§§§ 1466 ± 26.6 <0.001 <0.001 <0.001
HW mg/cm2 2.2 ± 0.05 2.4 ± 0.07 2.4 ± 0.05 2.1 ± 0.05��†† 0.52 0.39 <0.001
LV mass, mg 762 ± 65 1104 ± 66‡‡ 905 ± 26 1250 ± 70�� <0.001 0.025 0.97
LV mass, mg/cm2 1.9 ± 0.2 1.8 ± 0.1 1.6 ± 0.06 1.8 ± 0.1 0.7 0.17 0.15
Values are means ± SEM. BSA = body surface area, EDV = end-diastolic volume, ESV = end-systolic volume, SV = stroke volume, CO = cardiac output, LVIDd = left
ventricular internal diameter in diastole, LVPWd = left ventricular posterior wall in diastole, IVSd = interventricular septum in diastole, HW = heart weight, LV = left
ventricle, RV = right ventricle. Male obese N = 9; female obese N = 8; male lean N = 8 and female lean N = 6.
� male obese vs. male lean;
† male obese vs. female obese;
‡ female obese vs. female lean;
§ male lean vs. female lean.
One symbol P<0.05, two symbols P<0.01, three symbols P<0.001.
https://doi.org/10.1371/journal.pone.0232399.t001
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weight at the terminal measurements compared to lean animals (Table 1). When normalizing
these data for BSA, no significant differences were found (Fig 3B).
Cardiac histology
To visualize the presence of interstitial fibrosis, collagen in the heart was stained with Picro Sir-
ius Red (Fig 4A). Interstitial fibrosis was significantly higher in obese as compared to lean rats
(P<0.001; Fig 4B). There was no difference in Picro Sirius Red stained area between male and
female ZSF1 rats. Additionally, the content of collagen type I and type III fibers was quantified
in the LV sections (Fig 5A). Collagen type I fibers were increased in obese male ZSF1 rats com-
pared to obese females, while collagen type III fibers were significantly higher in obese rats
compared to lean rats (Fig 5B and 5C). No differences were observed in the collagen type I to
type III ratio in the ZSF1 rats (Fig 5D). Capillary density was evaluated in the ZSF1 rats by
Fig 2. Preserved systolic function in male and female obese ZSF1 rats. A) End-diastolic volume index (EDVI) was not significantly different between
groups. B) Cardiac index was decreased in obese male ZSF1 rats, while C) ejection fraction was preserved in all the groups. Means ± SEM. Symbols as in Fig
1.
https://doi.org/10.1371/journal.pone.0232399.g002
Fig 3. Obese ZSF1 rats show indication of diastolic dysfunction. A) Tissue Doppler Imaging showed that, already at an early age, the E/e’ ratio was
markedly increased in both male and female obese ZSF1 rats compared to lean rats. B) Left ventricular mass index (LVMI) was similar between the four
groups. Means ± SEM. Symbols as in Fig 1.
https://doi.org/10.1371/journal.pone.0232399.g003
PLOS ONE HFpEF in female and male obese versus lean ZSF1 rats
PLOS ONE | https://doi.org/10.1371/journal.pone.0232399 May 6, 2020 7 / 16
Fig 4. Increased fibrosis observed in obese ZSF1 rats. A) Representative images and B) quantification of histological staining of cardiac collagen fibers
stained with Picro Sirius Red. N = 4-7/group. ��P<0.01.
https://doi.org/10.1371/journal.pone.0232399.g004
Fig 5. Obesity leads to an increase in collagen type III fibres. A) Representative images and the percentage of B) collagen type I fibres and C) type III
fibres per myocardial area. D) Additionally, the collagen type I to type III fibre ratio was calculated in ZSF1 rats. N = 4-7/group. �P<0.05.
https://doi.org/10.1371/journal.pone.0232399.g005
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performing a lectin staining on LV cross sections (Fig 6A). Surprisingly, no differences were
observed between the four groups, although a trend towards a reduction in capillary density
was found in obese vs. lean animals (P = 0.08; Fig 6B). Consistent with the global LV hypertro-
phy, Gomori staining (Fig 7A) showed cardiomyocyte-hypertrophy and a reduced number of
cardiomyocytes per area in obese as compared to lean rats (P<0.001; Fig 7B and 7C). Capillary
to cardiomyocyte ratio was higher in the obese animals, although no differences were observed
between male and female rats (Fig 7D).
To further investigate the disease progression in the ZSF1 rats, the levels of growth differen-
tiation factor 15 (GDF15) in plasma as a marker for HF were measured. A significant effect of
obesity was found, with obese ZSF1 rats showing higher GDF15 levels compared to their lean
counterparts (P = 0.001; Fig 8).
Discussion
In the current study we investigated the development of early HFpEF in the female obese ZSF1
rat, a model characterized by the presence of severe obesity, dyslipidemia and mild hyperten-
sion, and compared the longitudinal disease progression between male and female obese ZSF1
rats. Obesity in the ZSF1 rats was associated with increased LV mass and diastolic dysfunction
while ejection fraction was preserved. Even though female obese ZSF1 rats did not develop
hyperglycemia, the absence of this risk factor did not seem to matter as severity of diastolic
dysfunction was comparable between male and female obese ZSF1 rats. Our findings indicate
that obese males and females both develop diastolic dysfunction.
Contribution of metabolic syndrome to the development of diastolic
dysfunction
Metabolic derangements such as obesity, hypertension, hyperglycemia and dyslipidemia are
recognized as important risk factors for the development of diastolic dysfunction and HFpEF
in humans [13, 22]. Obesity was observed in the ZSF1 rats, with an increase of 35% and 92% in
Fig 6. No microvascular changes were found in the ZSF1 rats. A) Representative images and B) quantification of the microvasculature stained with
Lectin. N = 4-7/group.
https://doi.org/10.1371/journal.pone.0232399.g006
PLOS ONE HFpEF in female and male obese versus lean ZSF1 rats
PLOS ONE | https://doi.org/10.1371/journal.pone.0232399 May 6, 2020 9 / 16
body weight at 26 weeks of age compared to lean males and females, respectively. Hypertrigly-
ceridemia (>16 fold in males and>17 fold in females) and hypercholesteremia (>3 fold in
males and>4 fold in females) were found in the obese animals. The dyslipidemia tended to be
worse in female rats which is consistent with a previous study in this model [23]. Hyperlipid-
emia in females has been associated with estrogen levels as an ovariectomy will correct the
hyperlipidemia, while estrogen administration in ovariectomized females will exacerbate
hyperlipidemia [24].
In our study, only male obese rats developed hyperglycemia from early age on. This corre-
sponds to findings in the ZDF rats, one of the parent strains of the ZSF1 rat, in which females
do not become diabetic when fed regular chow but only when a specific diabetogenic diet is
provided, such as the Purina 5008 diet or Research Diets 12468 [15, 25–27]. However, the nor-
mally recommended carbohydrate-rich Purina 5008 diet for the development of diabetes, did
not induce hyperglycemia in obese female ZSF1 rats compared to their lean counterparts [23].
In obese male ZDF rats, obesity seems to be the initiating factor for the development of diabe-
tes, as caloric restriction delayed and prevented the diabetic condition [28]. Ovarian estrogen
does not seem to be protective of diabetes development in obese female ZDF rats, as an ovari-
ectomy did not lead to overt hyperglycemia in these rats [29].
Fig 7. Obese female ZSF1 rats showed increased cardiomyocyte size. A) Representative images and B) quantification of cardiac hypertrophy stained with
Gomori. C) Number of cardiomyocytes, D) capillary-to-cardiomyocyte ratio. N = 4-7/group. ��P<0.01, ���P<0.001.
https://doi.org/10.1371/journal.pone.0232399.g007
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As the ZSF1 rats inherit the hypertensive gene from the SHHR parent strain [30, 31], mild
hypertension is observed in all groups as the normal systolic blood pressures of commonly-
used laboratory rats is 120–130 mmHg [32]. However, no further differences in systolic blood
pressure were found between lean and obese ZSF1 rats, similar to findings in ZDF rats [33]. In
summary, apart from hyperglycemia, important risk factors associated with the development
of diastolic dysfunction and HFpEF are similarly present in both male and female ZSF1 rats.
Systolic function is preserved in the obese ZSF1 rat
Ejection fraction was preserved in the obese ZSF1 rats during the whole study period (all
above 60%). Obese female showed higher EF compared to males, which has also been
reported in HFpEF patients [34]. Despite this difference, overall pump function was similar
between males and females. Notably, heart rate decreased over time in both male and female
obese ZSF1 rats compared to their lean littermates with the biggest decrease in obese males.
Although cardiovascular depression due to the isoflurane anesthesia might be a potential
explanation for the decreased heart rate, telemetric recordings in conscious male ZDF rats
also demonstrated lower resting heart rates in the diabetic animals compared to non-dia-
betic rats [35]. It has been suggested that the sympathetic system regulating the heart rate via
ß-adrenoceptors is impaired during diabetes, which might explain the more severe reduc-
tion in heart rate in obese rats with hyperglycemia [36, 37]. In ZDF rats it was reported that
specifically reduced ß1-adrenoreceptor activity contributed to the lower resting heart rate, at
a stage when ß-adrenoceptor responsiveness to pharmacological ß1-adrenoreceptor stimula-
tion was increased in these rats [35]. Impaired ß-adrenoceptor activity, due to desensitized
ß-adrenoceptor in response to increased sympathetic nervous system activity, is consistent
with the chronotropic incompetence in patients with HFpEF but may already be present at
rest in these animals because rats are sympathetically dominant [38, 39].
Fig 8. Higher levels of growth differentiation factor 15 (GDF15) in obese ZSF1 rats. GDF15 levels were measured in plasma collected at the end of the
protocol. Means ± SEM. Male obese N = 9; female obese N = 7; male lean N = 7 and female lean N = 6. �P<0.05.
https://doi.org/10.1371/journal.pone.0232399.g008
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Obese ZSF1 rats develop diastolic dysfunction with cardiac remodeling
Previous studies have reported impaired diastolic function with left ventricular hypertrophy in
male obese ZSF1 rats, however the cardiac phenotype of their female counterparts remained
unknown [13, 14, 16]. Here we showed that female obese ZSF1 rats also develop diastolic dys-
function, evidenced by an increase in E/e’, as early as 18 weeks of age. The severity in disease
progression was similar in obese female and male ZSF1 rats. Although current guidelines indi-
cate that diagnosis of HFpEF should not be based on E/e’ alone, as particularly E/e’ values in
the intermediate range only modestly correlate with filling pressures [40, 41], repetitive invasive
measurement of filling pressures and/or pressure-volume loops in this model is not feasible.
Additional evidence for a HFpEF phenotype is however evidenced by the observation that
hypertrophic cardiac remodeling was present in obese ZSF1 rats with preservation of the ejec-
tion fraction. Echocardiography derived LV mass as well as wet heart weight were increased in
both male and female obese ZSF1 rats (47% and 43% in males and females, respectively). It
could be argued that the increase in LV weight was due, in part, to the larger body weight of the
animals. We therefore present both uncorrected and body surface area-corrected data, as the
most relevant correction factor for the pathophysiology of HF in models of severe obesity, for
instance in the setting of weight loss due to caloric restriction [42], is a matter of debate [43].
Interestingly, LVEDV was increased in obese females, but not in the obese males. Similar
observations were found in the db/db mouse, in which a more pronounced increase in EDV
was found in obese females [44]. This finding is consistent with observations in normal weight
and obese male and female patients with left ventricular hypertrophy, in which only obese
females showed increased EDV compared to normal weight females [45]. This sex-specific
effect is not readily explained and is an interesting topic for future studies.
Obesity had a profound effect on cardiac remodeling, with increased cardiac fibrosis, colla-
gen type III fibers and cardiomyocyte size in both male and female ZSF1 rats. Endomyocardial
biopsies from patients with HFpEF revealed more extensive hypertrophy compared to HFrEF
patients [46]. Additionally, obesity had a significant effect on GDF15 levels, with higher levels
observed in obese rats compared to their lean counterparts. GDF15 is a distant member of the
TGF-ß superfamily and has been proposed as a biomarker in HF [47]. Circulating GDF15 levels
were elevated with HFpEF and were associated with an impairment in exercise capacity [48]. It
has also been found that GDF15 levels were positively correlated with myocardial fibrosis and
the levels of PICP and PIIINP, markers for the synthesis of collagen type I and III [49, 50].
The female obese ZSF1 rats show indication of diastolic dysfunction
The currently available animal models have attempted to reproduce the risk factors that lead
to the development of diastolic dysfunction, such as obesity, diabetes and hypertension [12].
Many of these studies have been limited to male animals, although it is well recognized that
there are differences in cardiovascular disease between women and men [51]. Female rats are
often excluded as their cardiac phenotype tends to be milder and more subtle compared to
male rats [52]. Recently, left ventricular diastolic dysfunction was shown in female swine in
the presence of hypercholesteremia, hyperglycemia and hypertension [53]. In obese mice,
females developed more severe obesity, increased blood pressure and a similar degree of dia-
stolic dysfunction compared to males [44]. In the current study we showed that female obese
ZSF1 rats develop diastolic dysfunction with cardiomyocyte hypertrophy and cardiac fibrosis,
in the presence of severe dyslipidemia and mild hypertension. Remarkably, despite the absence
of hyperglycemia, the severity of disease progression in the obese females was equal to the
male rats. This observation suggests that hyperglycemia actually has a minor contribution to
the development of diastolic dysfunction in this strain. Indeed, in 45 week old ZDF rats, severe
PLOS ONE HFpEF in female and male obese versus lean ZSF1 rats
PLOS ONE | https://doi.org/10.1371/journal.pone.0232399 May 6, 2020 12 / 16
diabetes only resulted in a relatively mild impairment of diastolic function [54]. Additionally,
in streptozotocin-induced diabetic female mice, diastolic dysfunction was observed despite
their less pronounced hyperglycemia compared to males [55]. This supports the notion that
hyperglycemia is not a critical factor in the onset of diastolic dysfunction, but that the combi-
nation of obesity and hypertension might be more important.
It could be argued that an ovariectomy in the obese female ZSF1 rats might lead to a differ-
ent cardiac phenotype, as in clinical practice HFpEF is predominantly present in elderly post-
menopausal women. An ovariectomy in obese Zucker females led to a decrease in plasma tri-
glycerides [24]. Thus, in contrast to what one would expect, an alleviation in the metabolic
syndrome phenotype was observed after ovariectomy and consequently also in the disease pro-
gression. Additionally, in obese female ZDF rats, ovariectomy did not lead to overt hyperglyce-
mia [29].
In conclusion, we showed that the female obese ZSF1 rat developed diastolic dysfunction
with cardiac hypertrophy and fibrosis in the presence of metabolic derangements. Their
observed cardiac phenotype was as severe as obese male rats, indicating that female obese ZSF1
rats should not be excluded from future studies investigating the mechanisms underlying dia-
stolic dysfunction and early HFpEF. We believe that this model is useful in enhancing our
understanding on the contribution of metabolic factors to this cardiac disease. Additionally,
this model is suitable for testing novel therapeutic interventions.
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